Progyny (PGNY) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
10 Apr, 2026Voting matters and shareholder proposals
Election of three directors: Lloyd Dean, Kevin Gordon, and Cheryl Scott, with board recommending a vote FOR each.
Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026, recommended FOR by the board.
Advisory approval of executive compensation, with board recommending a vote FOR.
Approval of amendments to eliminate certain supermajority voting requirements in the certificate of incorporation, recommended FOR by the board.
Approval of amendments to eliminate default supermajority voting for certain business combinations, recommended FOR by the board.
Board of directors and corporate governance
Board recommends all director nominees for election at the annual meeting.
Proposed amendments aim to simplify governance by removing supermajority voting hurdles.
Executive compensation and say-on-pay
Advisory (non-binding) vote on executive compensation is included, with board recommending approval.
Latest events from Progyny
- Proxy covers director elections, auditor ratification, pay reforms, and governance changes.PGNY
Proxy filing10 Apr 2026 - Key votes include director elections, auditor ratification, and reducing supermajority voting thresholds.PGNY
Proxy filing31 Mar 2026 - Strong utilization and new product launches drive growth amid stable competition and tech investment.PGNY
2026 KeyBanc Capital Markets Healthcare Forum17 Mar 2026 - Stable growth, high retention, and new market expansion drive a positive long-term outlook.PGNY
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Record 2025 revenue and margin gains, with 2026 guidance projecting further growth.PGNY
Q4 202526 Feb 2026 - Q2 revenue up 9%, guidance cut 5%, with record margins and $100M added to share buybacks.PGNY
Q2 20242 Feb 2026 - Targets $2.4B+ revenue and 20% CAGR by 2028, fueled by new women's health products.PGNY
Investor Day 20242 Feb 2026 - Utilization rebounded after a Q1 dip, with strong membership growth and a favorable outlook.PGNY
Jefferies 2024 Global Healthcare Conference31 Jan 2026 - Q3 revenue up 2%, net income and margins down; new clients, services, and buybacks offset client loss risk.PGNY
Q3 202414 Jan 2026